Imprime PGG Enhances Anti-Tumor Effects of Tumor-Targeting, Anti-Angiogenic, and Immune Checkpoint Inhibitor Antibodies

Imprime PGG (Imprime) is in late-stage clinical development as a combinatorial agent with several therapeutic modalities. Here we present pre-clinical mechanistic data supportive of Imprime, a soluble yeast β-1,3/1,6-glucan pathogen-associated molecular pattern able to prime innate immune cells in a...

Descripción completa

Detalles Bibliográficos
Autores principales: Chan, Anissa S. H., Kangas, Takashi O., Qiu, Xiaohong, Uhlik, Mark T., Fulton, Ross B., Ottoson, Nadine R., Gorden, Keith B., Yokoyama, Yumi, Danielson, Michael E., Jevne, Trinda M., Michel, Kyle S., Graff, Jeremy R., Bose, Nandita
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9178990/
https://www.ncbi.nlm.nih.gov/pubmed/35692755
http://dx.doi.org/10.3389/fonc.2022.869078

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9178990/
https://www.ncbi.nlm.nih.gov/pubmed/35692755
http://dx.doi.org/10.3389/fonc.2022.869078

Ejemplares similares